Eli Lilly’s tirzepatide is the king of the GLP-1s, but other options are coming

Eli Lil­ly’s tirzepatide is still the most ef­fec­tive weight-loss treat­ment to date, ac­cord­ing to de­tailed da­ta from its Phase III SUR­MOUNT-2 study re­leased at the Amer­i­can Di­a­betes As­so­ci­a­tion’s an­nu­al con­fer­ence on Fri­day.

The as­so­ci­a­tion said the once-week­ly GIP/GLP-1 re­cep­tor ag­o­nist, sold for di­a­betes as Moun­jaro, has demon­strat­ed “more weight loss in in­di­vid­u­als with di­a­betes than any oth­er med­ica­tion to date.” In the study, pa­tients with type 2 di­a­betes and obe­si­ty lost an av­er­age of 15.7% of their start­ing body weight af­ter 72 weeks of treat­ment, com­pared with 3.3% weight loss on a place­bo.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN